MONTREAL, Feb. 20, 2019 /CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that Health Canada has approved HUMIRA® (adalimumab) for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . Methotrexate increases the probability of remission with adalimumab or infliximab by 50% in patients with ...

As with other medications, Humira can interact with certain other drugs. It can also interact with some vaccines. An interaction occurs when one substance causes another substance to have a different ...

Amgen is introducing Amjevita (adalimumab-atto), a biosimilar to AbbVie’s Humira. Amjevita was the first biosimilar to Humira approved by the Food and Drug Administration in 2016. "With today's ...

Over two decades, Humira has been a blockbuster drug for AbbVie. The company sold more than $3.5 billion worth of Humira in the third quarter of 2023, 36% less than a year ago. Sales of Rinvoq, which ...

Three biologics appeared to increase herpes zoster risk, but 2 other therapies were shown to lower the risk, according to a study of patients in a Taiwanese national database. A new report shows ...